Welcome to the Royal Philips third quarter 2024 results conference call on Monday, October 28th, 2024. During the call, hosted by Mr. Roy Jakobs, CEO, and Ms. Charlotte Hanneman, CFO, all participants will be in a listen-only mode. After the introduction, there will be an opportunity to ask questions. Please note that this call will be recorded and replay will be available on the investor relations website of Royal Philips. I'll now hand the conference over to Mr. Leandro Mazzoni, Head of Investor Relations. Please go ahead, sir. Hi, everyone. Welcome to Philips' third quarter 2024 results webcast. I'm here with our CEO, Roy Jakobs, and our CFO, Charlotte Hanneman. The press release and investor deck were published on our investor relations website this morning. The replay and full transcript of this webcast will be made available on the website after the call as well. Before we start, I want to draw your attention to our safe harbor statement on screen. You will also find the statement in the presentation published on our investor relations website. I will now hand it over to Roy. Thank you, Leandro. Good morning, everyone, and welcome to the call. I want to start with the key highlights of this morning's release. We delivered strong improvement in profitability in the quarter, while sales were flat and orders slightly decreased as demand from hospitals and consumers in China further deteriorated. We expect impact from China to continue, therefore, we have lowered our full year sales outlook. At the same time, we expect adjusted EBITDA margin to be at around 11.5%, the upper end of the current outlook range. Within an ongoing challenging macro environment, we remain focused on successfully executing our three-year plan to fully capture growth and margin expansion opportunities. With patient safety as our number one priority, we are committed to delivering better care for more people. On to the key financial and performance highlights. Group comparable sales were flat on the back of 11% growth in Q3 2023, and further deteriorated demand in China. On the back of growth last year, we recorded a strong sales and order decline in China, driven by a further decline in consumer and hospital demand. This was beyond our China scenario from July, where we assumed stabilization of China, whilst timing of improvement was uncertain. We continue to deliver solid sales growth outside of China. Orders decreased 2%, also due to the decline in China. In the quarter, Diagnosis and Treatment orders remained solid outside of China, driven by, in particular, North America. Also, year to date, our orders grew 1%, including China, and we still expect order growth in the full year, including China, driven by the strength of the rest of the world, while there is certain uncertainty in China that remains. We delivered a strong adjusted EBITDA margin improvement of 160 basis points, driven by our continued progress on our execution priorities, improved gross margins from our industry-leading innovations and higher royalty income. Our free cash flow was EUR 22 million, driven by higher earnings and offset by working capital outflows, mainly due to seasonal phasing. We remain confident in our ability to drive further operational improvement, while the uncertainties signaled in the earlier quarters have intensified in China, and these are expected to continue. Focusing on China. In Personal Health, we saw a strong double-digit decline in sellout to consumers in the quarter, based on low consumer confidence and lack of big shopping festival sales. Adjusting to the new sellout run rate led to a substantial reduction in our sell-in volumes. We expect overall consumer sentiment to remain subdued in China, while solid in the U.S. and international markets. In China hospitals, the industry-wide anti-corruption measures and lack of impact of the national renewal program continued to significantly affect order and lead times. This also impacted modalities with shorter lead times, like Ultrasound, and therefore had an immediate impact on sales growth in the quarter. Visibility around the continued impact of the anti-corruption measures and timing of the government program remains limited. While the market conditions are expected to remain uncertain in China, it's a fundamentally attractive growth market for Philips, with strong underlying demand. Our order funnel is active in the country, and our commitment to a local-for-local approach, combined with our industry-leading innovations, focus on execution with excellence, deep understanding of consumers, and strong brand, places us well to respond to demand as it returns. Given the uncertain market conditions in China, we updated our outlook for the full year to a range of 0.5%-1.5% comparable sales growth for the group. Sales growth outside of China remains within the guided range of 3%-5%. We expected our adjusted EBITDA margin to be at around 11.5%, at the upper end of the current range, reflecting stronger margins from our industry-leading innovations, our financial discipline, and focus on productivity. We expect free cash flow to be around EUR 0.9 billion, at the lower end of the current range. Within an ongoing challenging macro environment, we are fully focused on successfully executing our three-year plan to drive value, and to date, we remain ahead of that plan. I'm confident that our innovative portfolio is well-positioned to help hospitals worldwide, addressing their staffing shortages, enhance productivity, and improve patient and staff experience. As it got recently also confirmed in my customer visits in Asia, Canada, and the U.S., our leading innovations are providing superior care for patients and consumers. Let me now provide you with some of the customer innovation milestones during the quarter. Carilion Clinic in the U.S. will expand cardiac care access through 11 specialized Philips interventional suites, allowing physicians to treat patients with complex cardiovascular conditions closer to home. We expanded our next generation cardiovascular ultrasound platform with FDA clearance of two important AI algorithms to enhance structural heart disease examinations as part of the global rollout of this technology. Demonstrating our innovation leadership in minimally invasive treatments, we secured FDA approval for the new LumiGuide navigation wire, which uses fiber optic technology to reduce radiation for both patients and physicians during minimally invasive surgery. In Personal Health, we launched our AI-powered Avent premium connected baby monitor, which offers cry translation and SenseIQ technology to track sleep, breathing and movements, giving parents peace of mind. And finally, last month, we welcomed investors and analysts for a show and tell event here in the Netherlands, followed by focused ESG site visit. The events provided a comprehensive update on the fundamentals of our businesses and of our exciting innovations, and included in-depth discussions and engagement with our leadership team. I want to thank again the investors who made the effort to spend a day and a half with us. Your engagement was incredibly valuable. I would like to continue with the progress we have made on our execution priorities. On patient safety and quality, as part of strengthening our culture, early this month, together with all employees, we spent a full day reflecting on the importance of patient safety and quality, the progress made, and the journey ahead of us to continuously deliver meaningful results. We continue to see a substantial reduction in the total number of CAPAs and improvements in our complaint management process in the quarter. We, including myself personally, have had multiple engagements with the FDA in the quarter to discuss progress made and what is more to do. Philips remains committed to patient safety and quality, and will continue to engage with FDA and other regulators on the shared mission to ensure delivery of safe and effective care for patients. With respect to our supply chain, our lead times are back to normal across all modalities. As mentioned before, and service levels continue to increase. Going forward, we continue to focus on supply reliability and on improving the flexibility of our network and supply base, including further regionalization and localization. Finally, our simplified operating model focused on a leaner organization, and that is resulting in faster and more agile decision-making, with productivity improvements of over EUR 1.5 billion to date. Also, on the back of a reduction of almost 10,000 roles. At the same time, we continue the journey to drive our culture of impact with care, building the right team with health tech capabilities. The last twelve months, our engagement score went up significantly, and we see growing confidence from our employees and other stakeholders. Now, over to Charlotte to take us through the Q3 financials and outlook in more detail. Thank you, Roy, and good morning, everyone, and thank you for joining us today. I'm very pleased to be speaking with you for the first time as Philips CFO. Before we dive into the financial results, I'd like to take a moment to introduce myself and share a bit about my background, for those of you who I didn't meet at our recent show and tell. I took over the reins as CFO earlier this month after over twenty years working in various financial leadership roles across the med tech and pharmaceutical industry, with a focus on supporting strategic growth initiatives, driving operational efficiency, and managing large-scale transformations. I joined Philips because I believe in the company's mission of delivering better care for more people and see significant opportunities ahead. I look forward to working closely with Roy and the entire executive committee to successfully execute our plan to create value with sustainable impact and drive financial disciplines. Continuing with our third quarter financial performance. Our comparable sales were flat in the quarter, and orders decreased 2%, both due to a decline in China. Year to date, order intake was 1%, despite a double-digit decline in China. We still expect order growth in the full year, driven by strength in the rest of the world, while the certainty remains in China. As a reminder, orders and order book account for around 40% of our revenue. The remaining 60% comes from growing re-recurring revenue streams, such as services and consumables, from book to bill business, and from Personal Health. Now, I'll provide some highlights around our quarterly segment performance. Diagnosis and Treatment comparable sales decreased 1% on the back of 14% growth in Q3 2023. We delivered solid growth outside of China, with both Image-Guided Therapy and Precision Diagnosis businesses contributing. The Adjusted EBITDA margin of 12.6% was in line with last year, despite lower sales, driven by improved operational performance, pricing, and productivity measures. Connected Care comparable sales were flat. Growth in Enterprise Informatics, notably in North America, and growth in Sleep and Respiratory Care, were offset by a low single-digit decline in Monitoring on the back of high teens growth in Q3 2023. Connected Care Adjusted EBITDA margin increased by 360 basis points to 7.3%, with improvements across all businesses, including an encouraging step up in Sleep and Respiratory Care. Personal Health comparable sales decreased 5% due to a double-digit decline in China, outweighing robust performance elsewhere. Adjusted EBITDA margin decreased year-on-year to 16.5% as operational performance improvements only partially offset the impact of lower sales. Year-to-date, the adjusted EBITDA margin improved by over 100 basis points. Sales in Segment Other were EUR 41 million higher than in the third quarter of 2023, driven by royalty revenues. Turning to operating highlights in the quarter. Adjusted EBITDA margin for the group improved substantially with 160 basis points in the quarter to 11.8%, driven by stronger gross margins from our industry-leading innovations, continued financial discipline, higher royalty income, and our productivity measures. Adjusted EBITDA margin improved 80 basis points in the segments, with higher royalties in Segment Other, contributing another 80 basis points. Our productivity initiatives delivered savings of EUR 188 million in the quarter, of which operating model savings were EUR 54 million, procurement savings were EUR 58 million, and other productivity programs delivered EUR 76 million, partially offsetting wage and component price inflation. Since the start of the plan in January 2023, we delivered over EUR 1.5 billion and are on track to achieve savings of EUR 2 billion earlier than anticipated. The effective tax rate was 24% in the quarter. Net income tax expense increased by EUR 33 million year-on-year, mainly due to lower tax benefits and higher income before tax. Financial income and expenses were a net expense of EUR 69 million, six million lower than last year, driven by higher interest income. On page 18 of our slide deck, you will also find the full year outlook for these items. Moving on to the balance sheet, we ended the quarter with approximately EUR 1.5 billion of cash and net debt of about EUR 6.5 billion. Our leverage ratio improved from two and a half times to 2.2 times compared to Q3 2023, on a net debt to Adjusted EBITDA basis. Adjusted Diluted EPS from continued operations were EUR 0.32 in the third quarter and increased 9% year-to-date, mainly driven by higher earnings. Free Cash Flow in the quarter was EUR 22 million, driven by higher earnings, offset by working capital outflows due to seasonal phasing. Based on our year-to-date performance and the deterioration of demand we are seeing in China, we now expect full-year 2024 comparable sales growth in the range of 0.5% to 1.5% for the group, as mentioned by Roy. At a business level, we expect Connected Care sales growth at the lower end of the range of 3% to 5%, a slight growth in Diagnosis and Treatment, and flat to slight decline in Personal Health. Restructuring charges and other items are expected to be in line with the outlook provided earlier this year. Given our continued execution and financial discipline, we expect full-year adjusted EBITDA to be around 11.5% of sales, which is a ninety basis point year-on-year expansion. We expect full-year free cash flow of around 0.9 billion EUR at the lower end of the range as a result of lower sales outlook, while continuing to drive working capital improvements. As mentioned earlier this year, our free cash flow outlook includes the agreed receipt of EUR 540 million from insurers to cover Respironics recall-related product liability claims, of which the majority is expected to come in the fourth quarter. The remaining payment related to the economic loss settlement in the U.S. made earlier this year is also included in this outlook. With that, I would like to hand it back to Roy for his closing remarks. Thanks, Charlotte. Let me close out by repeating the key messages of today. We delivered strong improvement in profitability in the quarter, with flat comparable sales and slightly lower orders as demand from hospitals and consumers in China further deteriorated, while we see growth in the rest of the world. We continue to make strong progress on enhancing execution and improving what's in our control, while external uncertainty intensified. We expect the impact from China to continue. Therefore, we have revised our full year sales outlook. At the same time, we expect adjusted EBITDA margin to be at the upper end of the current outlook range and cash at the lower end of the range. But in an ongoing challenging macro environment, we remain focused on successfully executing our three-year plan to create value, and to date, we remain ahead on sales, margin, and cash. We also have achieved significant milestones in resolving the consequences of the Respironics recall. I'm confident that our portfolio, innovations, and increased operational agility, positions us well to continue to capture growth and margin opportunities globally... and to respond when demand returns in China. With that, I would like to thank you for joining the call. We will now take your questions. Thank you, sir. If any participant would like to ask a question, please press the star followed by two times one on your telephone. Due to the time, please limit yourselves to one question. This will give more people the opportunity to ask questions. There will be a short pause while participants register for a question. We will now go to the first question. Your first question comes from the line of Richard Felton from Goldman Sachs. Please state your question. Thank you. Good morning for taking my questions. Just two for me, please. The first one is on the hospital equipment business in China. To what extent do you think the softness in your business in Q3 was driven by overall market weakness, or is there any Philips specific issues or market share losses that may have exacerbated the weakness this quarter? That's my first one. The second question is on gross margin. Obviously you had nice improvement year on year in Q3, despite less benefits from operating leverage. Are you able to maybe quantify some of the drivers of that margin improvement year on year, and whether we should think about those as a one-off or reasonably durable drivers of margin expansion? Thank you. Thank you, Richard. Let me start with China. So I think what we see is really a market development. And as I said, I think the difference was that we expected stabilization when we were in July, and what we have seen is deterioration, meaning that there is prolonged uncertainty and just the orders are not flowing yet into the market, and that also then prohibits sales to kind of strengthen. And that's something that we kind of have noticed in due course of the quarter. And as we also messaged, we don't see that visibility currently increasing. The same time, our order funnel remains active. We are in active dialogue with customers. I will also go back to China in two weeks, so, we remain active on the ground, but the visibility is low, and we have seen across market momentum that has not yet been picking up. On the gross margin, I think maybe, Charlotte, you can take the question. Yeah. Thank you, and indeed, we're very pleased with our operating margin expansion in the quarter, particularly driven by gross margin. And a few things I would highlight that really point to the durability of that gross margin expansion: first of all, we see an improvement coming from innovation. We see improved gross margins from innovation, and I point to a few of those innovations that we've done recently, like VM11 in Ultrasound and also Neuro Azurion in the biplane. And then, second of all, we do see operational improvements as well, as a result of the normalizing supply chain. And the third point I point to is really our continued financial discipline as we focus on what's within our control. All right, thanks for... Maybe to add, you see that all businesses gross margin goes up, and we also are on a continuous path of margin improvement. Since the beginning of the plan, you've seen that, of course, we have been having a very strong handle on what we can control. And for sure, that is the innovations and the margins it generates, the productivity actions we have been taking, and also the leaning out of the organization. So, that is something that you have been seeing dialing in consistently over the period into the results. That also means we are of course planning to date ahead, and also for the full year. You've seen us reiterating the strong confidence in our margin delivery, so I think that's being driven by the underlying factors that also on a business level have been materializing alongside the trajectory. Thank you. Thank you. Our next question goes to the line of Hassan Al-Wakeel from Barclays. Please state your question. Morning, thank you for taking my questions. I have three, please. Firstly, on China, can you talk about the quantum of deterioration in Q3 orders versus Q2, your current base case for Q4? How does this differ by modality, and when do you expect to see any stimulus benefit, based on your customer conversations, if at all? Secondly, against the backdrop of 1% order growth year to date, how are you thinking about the achievement of 2025 targets, given a worsening China? And thirdly, how is order momentum trending outside of China, particularly in the U.S., and how confident are you in driving this post-RSNA and into next year, perhaps providing some offset against, China weakness, persisting into 2025? Thank you. Thank you, Hassan, for the questions. Let me start with the first one, so in China, and I think what is important to call out when we talk China, it's two drivers that really kind of saw deterioration. It's the hospital side, but for sure, it has been also the consumer side, and that has also been a quite rapid decline because actually that, as you know, is responding to the sell-out trends, and what we have seen happening is that actually, based on already a slower first half, the consumer confidence further deteriorated in Q3, including then also the adjustment of the expectations of sales, and in particular, also for the big days, and the 11.11 upcoming. So you saw that the consumer kind of decline was significant, and also, I think, worse than we expected mid-year. And on the hospital side, we've seen that kind of the visibility on what's happening on the ground still remains low in terms of when it really materializes. We are close with customers. We have been working on order funnel. We also kind of have been preparing some of the list to go into kind of the requests for the renewal program. We just don't have seen it coming into the customers for decision making, and that's something that is regardless of modality. But there are different impacts per modality, because across the modality, of course, you have some that have an immediate impact, even in the quarter or the half year, when the kind of the order doesn't come, like the shorter style businesses. So you saw some more pressure on those also from a sales perspective. And then you have also the impact, of course, from the prolonged kind of delay in orders that we have seen, for example, in IGT and in Precision Diagnosis. So I think that is the trends that we have seen across the market, which we believe are truly a market phenomena. We keep preparing well for China when it comes back. So actually, we expect that that when it returns, we are well positioned with our local innovations, with the customer proximity that we have. But then, I think until that, and that maybe is a nice bridge to what you also asked for, what we're doing outside, then it's really, for us, important to drive that momentum outside of China. And there, as we also shared in the update, we have seen strong momentum. Actually, year to date, order intake, indeed, including China, is 1%, but there is a distinct different pattern between double-digit decline in China and then, within our range, kind of growth outside of China. Within outside of China, I'm particularly pleased with North America, because there, actually, we see even a faster order growth than in some other parts of the world on the back of a very strong North American market and healthcare market. We also actually see the consumer market strengthening, so we are dialing up our kind of pace in North America across the businesses. You saw, of course, the D&T order intake was particularly encouraging in North America in this quarter. But also, if you look kind of year to date, we have had a very strong order growth in North America, and we also expect full year to close out with a strong performance. That, of course, sets us up also for further growth in that important market. And that then also relates to kind of 2025. While we are not here to guide for 2025, I think it's important that the progress that we have been making on the plan really underpins also our 2025 trajectory, where we will remain very focused on, firstly, what we can control, which is driving strong contained margin expansion, delivering on the cash, growing outside of China. Then China, we will kind of look into, depending on when clarity comes further on the China momentum. So that's something that kind of we are razor focused on, and that also sets us up for continuing to deliver on the plan. Because also on that note, right, I think it's important that if you look on the delivery on the plan to date, we have been over-delivering on growth, sales, on margin, on cash, and of course, we also have been really clarifying some of the uncertainties and risks that there were at the beginning in 2023. So we stick to the plan, focusing on driving strong innovations, improving the margins of those innovations that we see really now coming through in gross margin, and then actually to look at where we can capture the growth and really capitalize on that. And I spoke about North America, but I've also been to Indonesia, where we have been dialing up growth, and we are going after strengthening the performance in the market, and not only there. There are other parts of the world that also give those opportunities, that we are fully going after. Perfect. Thank you. Thank you. Our next question comes from the line of David Adlington from JP Morgan. Please state your question. Morning, guys. Thanks for the questions. Firstly, maybe just on other mature geographies, which were down 10% in sales, I think. Maybe if you could pull out any particular areas of weakness there. And just following on from that, also, North America, only 1% growth, just maybe you could split that out by Personal Health and D&T. And then secondly, just in terms of the restructuring charges, EUR 165 million coming in Q4 with EUR 100 million on connected care, mostly on asset impairment, I think. Firstly, why not take that in Q3? And secondly, any further color you can give us around that asset impairment in connected care would be useful. Thank you. Yeah. Thank you, David. Let me take those questions. So, first, your question around the other mature geographies, that is really driven by a very strong comparable that we saw in Q3 of 2023, and also a little bit of softness in Japan as well. So moving on to your second question around the adjusted items. As I said in my prepared remarks, there is no change to the full year outlook we provided for incidental, so it's still in line with the 330 basis points we said earlier this year. And of course, Connected Care is a very big part of this, as there were Consent Decree-related charges, Respironics field actions charges, and what have you. Really, if you look at Q4, our EUR 100 million guidance for Connected Care doesn't really stand out much. We've seen some higher numbers, we've seen some lower numbers, and there's really no further impairment included in those numbers, either. And we're really laser focused on driving the same financial discipline that we're driving in our adjusted EBITDA margin, also in our adjusted items as well. That's it, and then maybe just to break down that North American growth by, maybe by Personal Health and D&T. So we see growth actually in both sides in North America. So actually that is something that we have, and actually we see it also dialing up in both areas. So kind of Personal Health started the year a bit slower, but actually is coming up. And then also now we see that the health system side, based on this strong order intake, is coming up. Also to be noted, we're coming off very strong double digit comparables last year, and that, of course, Q3 last year was a very strong quarter at liquidating the backlog, and that's something that we are kind of working against in terms of the comparable. But if you look underlying, we see the momentum growing both in consumer as well as in the health system side and also across segments. All right. Thank you. Thank you. Our next question comes from the line of Lisa Clive from Bernstein. Please state your question, Lisa. Hi there. Two questions. One, how should we think about pricing over the next one to two years? My understanding is like, for like, used to be slightly negative, due to trying to offset the cost inflation. It's more flat to slightly positive now. How do you think this will evolve? You know, will your sales force revert to discounting, perhaps driven by peer behavior, or do you think we're sort of in a somewhat new norm in terms of like-to-like pricing trends on equipment? And then, second question around your imaging business. You saw a lot of market share losses in several modalities, namely MR and CT, during the pandemic. Now that your supply chains have stabilized, et cetera, how are you doing relative to peers, and do you think you can regain some lost ground in the next year or two? Yeah, let me take the first question, Lisa. Thanks for your question. I'll take the pricing one. So indeed, as you said, in Q3, we did see a pricing benefit both in diagnostic and treatment as well as in connected care, as we still see the higher prices flowing through from our order book into our P&L, which has really helped our margin development. So if you look at the outlook, we have to see how it goes in the next quarters, and we have to see how it evolves from a competitive standpoint. So we remain a little bit fluid. However, what I would say is that we've seen and continue to see very good progress with material price reductions, which helps improve our gross margin, as I noted earlier. Then maybe from a PH perspective, we don't really see further pricing upside, given the subdued consumer sentiment, but we are staying on top of any inflation developments that we might see. Let me maybe take the second one. So on the IGT, indeed, it was important, based on our progression of supply chain, that we're fully back with the lead times now. And also, the strong innovation and momentum we are seeing, both in MR with the BlueSeal, CT, with the new launch of the CT 5300, with AI to really kind of drive productivity and the spectral. But also actually the DXR renewed portfolio that we launched last year actually is really gaining momentum. So we see actually that we're also kind of climbing back, and that's also something that you saw, for example, in the D&T order intake in North America this quarter, which was strong. So we see kind of we are making inroads. So we are fighting back on that, on that front based on the innovations, but also the better execution ability that we have been working on very strongly. As you know, for D&T, China is important as well, so we remain focused on kind of getting ready for when the demand returns. And then the IGT side has throughout been very strong. We continue to kind of see the momentum there also now with the newly launched NeuroSuite and the biplane as well as the device business, where we see strong momentum based on the procedural growth. You saw that we got the LumiGuide now approved by the FDA. That's another really unique kind of proposition that we will add to the portfolio now to support our kind of growth in the device space. Actually, we are building that momentum, and that's also how we have been seeing it growing in the total order book. Okay, thanks. I'll hop back in queue. Thank you. Our next question comes from the line of Graham Doyle from UBS. Please state your question. Morning. Thank you. Just a couple of questions. Well, actually, both related to China. Just firstly, I mean, some of the comments from your peers over the last kind of month or two sounded like they were kind of growing in confidence and seeing a little bit more certainty in the Chinese market. From your perspective, do you think there's less certainty now or less visibility than there was maybe a quarter ago? It could have sounded like that. So it'd be just good to get a sense as to where you think you are in that improvement or not improvement of the backdrop, and then just when we think beyond. When demand does come back and we're in a kind of a sort of a normal environment, are you expecting that environment to be different? So, for example, we've seen as part of the stimulus, there's a little bit more tendering that's going to happen this time. Do you expect more measures like that to be in place? Do you expect any shifts in the competitive dynamics? Just to understand what you're thinking about when you think, when you kind of continue to say China remains attractive. Thank you. Yeah, thank you, Graham. So on the visibility, actually, and that's also what we reflected, visibility for us remains at this point in time kind of difficult, right? It's hard to predict what is happening exactly. I think when we were midterm, we said kind of we expect at least stabilization. That was also kind of backed on the government that was saying, "We want this program to materialize in 2024." The reality is that 2024 is running out, and if it has to kind of materialize, there's not a lot of time left, and that's actually something that we did see in 2024. So that's where at for the moment, we keep at the point that we say visibility is limited. And that means that indeed, we then have to prepare more on the fundamentals, where we have been ensuring that we have the local innovation, that we're close with customers on the funnel. And if you talk about the kind of fundamentals that we need to be prepared for, and that's also something that we're hearing back from our customers, these new procedures that are being implemented, happily implemented, I think will have a prolonged period of impact, meaning that duration of approvals will get longer. So depending where there's just more oversight, will take more. We have not seen the specification kind of change, so we feel fully entitled to compete with our portfolio. We know that actually there are significant demand that we were leading with, for example, the BlueSeal, and even also, the spectral interest in, in China very strongly. So, and also Ultrasound traditionally has been a very strong business for us as well. So we don't see that necessarily changing in terms of competitive dynamics. We have said earlier that, the long-term growth prospects for China, long-term attractive. Although we also said that it's not the China that we know from ten years ago, because just the macroeconomic environment in China is different, right? And that's the whole market and the whole kind of economy that is growing less strong, and therefore, that also has some impact on the spend in the different segments that we see coming in. That does not mean that it's not, kind of attractive. It does mean that kind of it will be attractive in the near future when it comes back, the only visibility we don't have. And that means that we continue to focus on the rest of the world to dial up momentum there, as we also have seen happening in due course of this year. And then finally, maybe on China, if you look at some of the underlying diseases like cardiac, like neuro, there is significant interest, right? And we are working also with our IGT suite, some of our imaging suite, to see kind of how we can build on the practice that we have had outside of China. And the staff shortages are very significant. So also some of the AI solutions, like SmartSpeed and others, really add value in that market. And what you also know from our share development to date in China, IGT, we have been growing share. We were kind of challenged a bit with our supply chain challenges also in DI. Now, we are fully back there and have ramped up that supply chain also in China, so that would kind of give us full opportunity to play part of the momentum if it comes back. Okay, great. That, that's really helpful. Thank you very much. Thank you. Our next question comes from the line of Hugo Sauvé from BNP Paribas Exane. Please state your question. Hi, hello. Thanks for taking my questions. I ask three, please. First, follow-up on China. Just, Roy, on your comment around the funnel of order, is that just a function of more meetings with customers, continued strong interest, or, actually orders slowly, virtually moving into the execution phase? And if you can explain a bit of what type of modalities, you are seeing, strong for, for those four. Second, on, 2025, follow-up to Hassan's question. How much of the 2025 targets relied on China picking up now, and how comfortable do you think you are with consensus forecasting, eighty base, margin improvement, given the uncertainties in the country, but also the, the benefits from the efficiency plan on the other end? Lastly, in Sleep and Respiratory Care, I think margin was progressing sequentially, Q1, then Q2. Can you maybe let us know where you are in terms of profitability for that business and what the right sizing of that business that happened in Q3 exactly implies? Thank you. Yeah. Thank you, Hugo. Let me go into your different questions. So on China, so on the order funnel, that's kind of based on our discussions with customers, and as a result, what are the opportunities that we have in our books that we expect to materialize when China comes back. That is not yet of orders flowing into the China customers and approvals, because that's actually where the lack of also showed in the decline of orders and the decline of sales in the market. So I think there's clearly a difference between the activities, the customer needs, the discussions we are having, and also then how that materializes and how it materialized in quarter three, and also how we have taken that into Q4, and I will be back in China next week. There will be a big China expo, which we are part of, and we are also invited for. So yeah, the momentum in terms of the dialogues keep happening, but we see just that, the kind of flow-through in terms of real orders and then sales, that's where the current slowdown is hitting us and I think hitting the market in full. Then secondly, if you look to kind of 2025, we're not guiding for any 2025 currently. So what I said before, we remain fully focused on executing the three-year plan that we're on, which we also have seen is working. We are planned to date, or, we are kind of ahead. Demand in the rest of the world remains solid, and that is also we saw we got it for this range this year. We continue to build on that momentum. The uncertainties that we signaled earlier in China intensified and we expect to continue, so that there's an impact we also expect into 2025. But again, too early to discuss specifically. If you look at what we can control, and we were very confident on the further operational improvement, focusing on margin and cash, I think we will not hold back in any way or form. The productivity is coming through. We have seen that we realized EUR 1.5 billion to date. We are ahead of that, and we will continue to drive that strongly, and we believe also that that will show in the kind of continued progression on that trajectory, as well as in the cash progression, that results of the combination of better underlying operational delivery into next year. So we are well positioned to capture growth when it comes, but in particular in China, we need to be more cautious on that, and we are because of the lack of current visibility. So that's kind of how we look at how we go into 2025. Stay the course on the plan, focus on the controllables, confident in that, growth outside of China, fully dialing up where we see the growth to capture it, and in China, kind of being modest based upon the lack of visibility. And then maybe I could take the question on S&RC, and S&RC return to market is going really well, and according to plan, customers really want us back in the market, and they like our innovation. What we see as well is solid sales in Sleep and P atient Interface outside of the U.S., and then from a profitability perspective, we, and again, saw an encouraging margin step up in S&RC, and in fact, in our whole Connected Care segment, which just speaks to the underlying resilience and strength in our EBITDA margins, which keep on improving and which we are laser focused on now in Q4 and also next year. Thank you. Thank you. Our next question comes from the line of Julien Dormois from Jefferies. Please state your question. Hi, good morning, Roy, good morning, Charlotte. Thanks for taking my questions. I have three, if I may, and mostly housekeeping, I guess. But first one relates to the royalties, because obviously, that was a quarter with a nice contribution from that line. So just curious how much of that should be seen as, let's say, recurrent? And I know those are lumpy by definition, that really provided a nice boost to the margin in the quarter. So just curious, how what you should make of that, and how do you see royalties evolving into the fourth quarter and maybe into twenty-five? Second question relates to the potential or the risk of U.S. tariffs making a comeback, depending on the election outcome in a few weeks from now. How do you see the situation on your side and in what way the situation would be different from what it was in the first mandate back in twenty seventeen, twenty eighteen, if Trump were to be elected, or if any kind of tariffs were to be reinstated? And the third question is very much housekeeping, but could you just remind us how much of a contribution to sales China represents at the group level, but also maybe giving a bit more insight into PH versus the rest of the group, please? Okay, thank you, Julien. Let me take the first question on royalties. So indeed, as you said, in the quarter, royalties supported roughly 80 basis points of improvement of our EBITDA improvement. And if you then look at the full year, our guidance is that roughly we've increased our guidance by roughly EUR 20 million. So that means from a full year outlook perspective, only 10-15 basis points of that 90 basis points improvement comes from royalties. So really underlying, we continue to drive strong EBITDA margin improvement in line with just focusing on what we can control. And I can assure you, we will not stop there if we can do more. Maybe on the second one, on the tariffs, we have been really working on making our supply chain resilient to also be prepared for scenarios that could evolve across the world, because actually that is of course happening in multiple potential countries. So actually to go for local-for-local for China, but also to regionalize our supply chain for North America, really helped us to kind of be prepared for changes potentially in goods flow of the world. So we are now kind of building three regional strong axes where we can supply from, and that's also showing in the resilience of the current supply delivery and the lead times and the service that we have on that. We also have dual sourcing introduced, so a lot of focus and progress made on that to be ready for any adjustments that we need to kind of adjust to. And then maybe last point, the organizational agility also increased based upon the simplification, and I think that also helps us to kind of turn quickly towards changes if need be. And that then brings me to China. If you look at the China kind of size, you have the... And I think it's important to understand that approximately 10% is China. But you see, a difference, a distinct difference in Personal Health, which is more sizable, and therefore, also the impact this quarter was more sizable and also for the half year is more sizable, given that that is a significant part of that business, more than the 10%. And then, you have the Europe piece, where you see that from a total segment, D&T is more dependent on China than, for example, Monitoring. It's not that Monitoring is immune to China, there are some dependency, but just much smaller. So the two segments that are hit most are D&T and PH. And I said PH was the one that really kind of showed a significant slide also into Q3 and the second half. On the opposite, you also know that once consumers demand and confidence would go up, you also can more quickly catch up. But that's again, we don't want to kind of prelude that until we have the visibility on when that would happen. Super helpful. Thank you so much. Thank you. Our next question comes from the line of Robert Davies from Morgan Stanley. Please state your question. Yes, thanks for taking my questions. My first one was just on your order outlook for the full year being up 1%. Just had a couple of questions on that. Obviously, Personal Health, you still have a tough comparable in, I think in the fourth quarter of 2023. So just was trying to get a bit more color just in terms of what was underpinning your conviction in keeping orders positive. And maybe just on the order front, what just sort of looking back over the last two quarters, you've had quite high volatility between the orders up 9% in the last quarter, down 2%. What sort of really changed on a sequential basis? 'Cause that's obviously a pretty big move quarter on quarter. My second question was just around trends in Personal Health, whether you'd seen any sort of downtrading. You'd mentioned, obviously, consumer confidence has softened in China, but has that resulted in anyone downtrading within that segment, or is that just a sort of operational leverage effect? Thank you. Yeah, so on the first one, so, operational full year, so, and also even the order flow through the quarters. So I think. Mm-hmm. What you see is that kind of we are year to date on +1% with a double-digit decline in China, and then an offsetting growth in the rest of the world. In the rest of the world, currently, North America is really coming up very strong in order growth. What we do see in North America, and that's a bit where you see also some of the lumpiness coming in, that you have, especially Monitoring with very sizable deals. You saw some of that in Q2. We're working on more, and that has an impact. The other piece is also that some of the service growth is also kind of playing part because you're converting some of equipment also into service. That makes that kind of the quarter on quarters kind of flow is becoming a bit less predictable, and you need to look at a longer term trend. And that's why I'm excited to see that actually we are dialing up that order momentum across the globe, and in particular, in the strongest market of the world, which is North America. And we also expect that to continue. That's also what we set for the full year outlook, and that we also will take into 2025. Then on PH, we see also there, the two kind of growth track that we see in the world. So you see China under significant pressure. It's not necessarily a specific downtrade, it's just really a lack of sell-out. Mm-hmm. Because actually, if you look to how we are doing in China, we have been gaining share in Grooming. We see that actually in Oral Care, some of the new brands actually are stepping out because they were trying to get in, and also sometimes with the lower value propositions, and they see that that momentum is being under pressure. Of course, we need to be looking at the overall market momentum globally as well, and we see that it's picking up in other markets. We had the new launches, Mother & Child Care you saw with the kind of clearance on the AI baby monitor. Actually, Mother & Child Care has been on a very strong trajectory, of course, with orders also outside of China. So we also see that we can capture the margins in Personal Health, and that's also we see that we're holding EBITDA strongly, despite a significant volume decline. I think the overall value capture out of Personal Health, based on strong innovations, we see still as strong and also going into next year. Thank you. Could I just ask one quick follow-up, and just where your order book is now relative to where you were at the start of the year? In what specific sense? In sort of absolute magnitude, is it bigger or smaller now than the beginning of 2024? We are. Because as you mentioned, year to date, orders are up one. You've got sales growth that's panned out as well. So I just wondered where you were in terms of order book, in terms of the conversion. Has it gone up or down since the beginning of the year? No, it's more... I would say it's more or less, flat, kind of in terms of there's no significant change versus the beginning of the year. You see that. Mm-hmm. Kind of fact, there's not a lot of delta between the current sales and orders. Of course, there's a big delta in between China and the rest of the world. So we are. Mm. Building up the momentum in orders, and I think you see therefore that kind of, that will kind of start to show also, towards, next year. And then we also still had some depletion of backlog, right? Mm-hmm. Because that was where it was happening, in particular in the PD space, MR and which was having the supply chain challenges, as you know. So it really depends on the modality, kind of, where you see the different trends. But overall, I would say it's more or less in line, on a healthy level. We are growing the momentum outside of China, but China is having a big impact. Understood. Thank you. Thank you. Our next question comes from the line of Falko Friedrichs from Deutsche Bank. Please go ahead. Thank you. Good morning, everyone. My first question is on your sales guidance cut for 2024. Considering your previous answer that China is about 10% of group sales, it seems to be a pretty dramatic cut here. So is it fair to assume that the rest of the world grows rather at the low end of the 3%-5% range this year? And then my second question, and sorry if I missed it, on China stimulus, what's your latest to the best guess when these measures start to kick in? Or is that a topic that we sort of should put on the backseat for now? Thank you. On the outlook, focus, as I said, in China, you see distinct bigger impact from Personal Health. And that has been really kind of material for the Personal Health business. You also saw the growth in the quarter, right? Turning significantly negative. That's also where you see that actually it's not 10% for Personal Health, actually is significantly more. So that was the big impact that you see, and therefore, also for the rest of the world, whilst we don't guide upper or lower, is actually solid in the growth range that we have been guiding for. And also, with the lack of visibility, we took some prudence into that outlook for the year, which I think is the reasonable approach to take, given that we saw the Q3 developments. Let's also now be cautious on Q4, what is happening on the ground, and that's something that we took into the outlook. Thank you. And then stimulus in China? The stimulus in China, yeah, that's... I think, well, I think where we didn't see that, coming into, the market yet. I think that also has been part of why we, on first instance in July, were expecting some of that might come in, and that would then stabilize the market. That did not happen, right? And therefore, we, kind of also remain prudent on that. We know it's, there's discussions on it. We know that kind of, customers put in their lists, but we have not kind of seen it materially coming into new order flows, that we can act upon. Okay, thank you. Thank you. The next question comes from the line of Ed Ridley-Day from Redburn Atlantic. Please state your question. Hi, thanks very much. Just a couple of follow-ups, please. I think historically on Personal Health, you've highlighted that it was around high teens or even slightly higher as percent of sales that's coming from China, at least until last year. If you could confirm that was reasonable thinking. And in terms of the D&T business, obviously tough comp, you've highlighted. We haven't really talked about the different growth between the three units there. Commentary from your peers suggests clearly IGT market is very strong on the base of procedure recovery. So could you give any color at all on the growth in IGT, Imaging and Ultrasound within D&T? Thanks. Yeah, so on the Personal Health question, so, you are right with high teens, right? So that's also what I, I signaled earlier, right? So significantly higher than the 10%, so it is indeed a sizable chunk of the Personal Health business. Now, I think good news was that we're also seeing, a very solid growth outside, and that's dialing up, but it's just kind of the impact, and especially than if you have it one quarter or two, it has, a sizable impact on your total Personal Health segment, impact, and therefore our total sales. So I think, you're right in that assumption. Then on D&T, indeed, IGT is strong, but also in PD, we have been seeing growth, sales growth momentum. MRI, for example, where we now have lead times back to market, we have been really dialing up that sales momentum also on the ground, and you see that dialed into the D&T segment. Ultrasound is more disproportionately dependent on China, so also you see that impact reflected in the Ultrasound run rates because we have seen that slowing with a relative higher dependence on China in the total mix, because they were earlier significantly built up. We expect that over time to come back when China comes back, but for the moment, that for example, impacted the run rates in PD. Great. Thanks very much. Thank you. Due to the time, the last question is a follow-up question from Lisa Clive of Bernstein. Please go ahead, ma'am. Hi, thanks for giving me my follow-up question. Could you comment on trends in North America? It seems like you have strong demand, good order book. I think some investors have been concerned that a lot of the stability in the business has been dependent on that market and, you know, concerns that it could potentially soften. So if you could just comment on what you're seeing there, that would be helpful. Yeah, so if I look to the North American market, and I think that is first of all, it comes back on the back of the underlying fundamentals, so the financial strength of the system really has been sequentially strengthening since COVID, right? Where we came out of a negative market, where most of the hospitals were in negative territory, they started to become neutral. This year, we see positive, and you see especially the stronger systems turning more positive and actually are consolidating, acquiring, and that then also leads to opportunities in further standardizing their platforms onto kind of strong offerings, and that's where kind of we are included, and we see then also the impact in our order book. I think that is something that is one trend. The other trend, which you also have seen, there is a lot of patient demand, and there are still wait lists in North America, which was quite unprecedented before COVID because the system was being able to deal with quite some volume. And that's driven by, on one hand, kind of the staff shortage that's really playing part. But it's also in terms of, dialing up the procedural volume, and that's where you see it kind of has some of the demand in IGT. That is strong. You see the procedures growing. That is strong and driving fundamental growth. And then also with the radiology challenges and the pathology challenges, of course, our workflow solutions for radiology and pathology are really in demand. When I was in Chicago two weeks ago, this was really at the top of the town with the big systems. I was at AdvaMed conference. This is a big part. We expect the same to come at RSNA. So we see that the underlying is a healthy demand that needs to be fulfilled and catered for. Then it's more also about kind of what is the implementation ability for the market to kind of dial up, because there are also staff shortages in some of the installation capacity. But I think we're yeah quite positive on the trends that we have seen in North America with sequential strengthening and improvement. Okay, great. And just one last follow-up question, circling back to China. You know, you were growing about 4% in the five years before the pandemic. You've now guided 5%-6%. Obviously, this year is gonna fall well short of that, given the rollover in China and a few other factors. But, if you grow 5%-6%, and if China is not a double-digit growth market and, you know, sort of continues to limp along, where will that growth come from, and how confident can we be in that outlook? Yeah, I think. So there are two parts to in answering that, Lisa. One is, of course, we are looking at the different segments that we have within Philips, where we also shared in the show and tell that we're active in certain part of the market. For 70%, we are part of the market that actually is growing on average higher pace, and that is then globally seen. But we also see that pace very much outside of China. So that's something where we will go after, and that is in IGT, that's in Personal Health outside of China at the moment, that is kind of with Ultrasound, that is with Monitoring. So, very strong segments where we see kind of that there is the long-term growth potential and also margin potential. And then you see that kind of there are some of the markets that are also more dependent on China that will have more significant impact to cater for. And last but not least, it's not that we don't expect China to come back, right? It's not that this will be a trend that will be there forever. We just don't know exactly when it's going to come back up. And when it comes back up, we also expect there will be demand, because there is just a significant patient base to be catered for and significant amount of hospitals in need of solutions. So we also expect that will start to contribute then, if you take a bit of a longer-term perspective. But in the plan period that we originally looked at, of course, now we need to cater a bit more for growth outside of China. And that's also something where we see that we are dialing up momentum, and you also saw that this quarter, right? So we said we delivered outside of China growth in line with our 3%-5% range, and we also continue to fully focus on that. And then I mentioned earlier, North America is important in that. We have growth markets like Indonesia, like some of what we see happening in Saudi, but also what is happening in LATAM. And ultimately, kind of it's driven on the back of standard setting and strong innovations that we have, where we know that demand is there. So we are kind of well positioned to capture the growth when it kind of happens, and we need to make sure that, and we have been working on that with execution of our plan, that supply chain works, which currently is fully on par, and also that we have an agile organization that can go after it with a cost-competitive mode, because the margins will remain razor focus in all that we do. So that kind of we keep that trajectory just ongoing, kind of, more independent of the sales momentum that we see globally in the market. Great. Thank you very much. Thank you all. That was the last question. Mr. Jakobs, please continue. So thank you all for dialing in. As we said, I think, what we see in the world currently is strong delivery of margin that we also reiterated for the full year at the upper end. Sales that we adjusted, signaling further deterioration in China, and also taking a prudent approach onto that into Q4, whilst we are dialing up momentum in the rest of the world, and we stay fully focused on executing on our plan, where plan to date, we're ahead on sales, margin, and on cash, and we have been making significant progress in resolving some of the issues with the recall. So we focus on what we can control. We keep driving that with strength and with pace, and look forward to talk to you in upcoming opportunities. This concludes the Royal Philips third quarter 2024 results conference call on Monday, 28th October, 2024. Thank you for participating. You may now disconnect.